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Abstract: Prostate cancer is the second most common cause of cancer death among men. It is
an asymptomatic and slow growing tumour, which starts occurring in young men, but can be
detected only around the age of 40–50. Although its long latency period and potential curability
make prostate cancer a perfect candidate for screening programs, the current procedure lacks
in specificity. Researchers are rising to the challenge of developing innovative tools able of
detecting the disease during its early stage that is the most curable. In recent years, the interest
in characterisation of biological fluids aimed at the identification of tumour-specific compounds
has increased significantly, since cell neoplastic transformation causes metabolic alterations leading
to volatile organic compounds release. In the scientific literature, different approaches have been
proposed. Many studies focus on the identification of a cancer-characteristic “odour fingerprint”
emanated from biological samples through the application of sensorial or senso-instrumental analyses,
others suggest a chemical characterisation of biological fluids with the aim of identifying prostate
cancer (PCa)-specific biomarkers. This paper focuses on the review of literary studies in the field
of prostate cancer diagnosis, in order to provide an overview of innovative methods based on the
analysis of urine, thereby comparing them with the traditional diagnostic procedures.
Keywords: prostate cancer diagnosis; biomarkers; electronic nose; olfaction; gas chromatography;
VOCs; trained dogs
1. Introduction
Prostate cancer (PCa) is the most common diagnosed cancer in Europe and America and the
second most common cause of cancer death among men [1]. The National Cancer Institute estimates
161,360 new cases of PCa and 26,730 deaths in 2017 [2].
PCa is an asymptomatic tumour, which starts occurring in men aging 20–30 years, but can be
detected only in the fourth-fifth decade [3]. Indeed, symptoms appear only when the disease has
reached an advanced stage, reducing the number of adoptable treatments and patients’ chances of
surviving [4].
The long latency period of PCa and its potential curability in early stages make this disease a
perfect candidate for screening programs [5]. Nevertheless, PCa diagnosis is challenging because of
the late onset of symptoms and the limits of the current diagnostic procedures.
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Serum prostate specific antigen (PSA) level and digital rectal examination (DRE) constitute the
major screening tests for PCa diagnosis, while the transrectal ultrasound-guided prostate biopsy
(PBs) provides the final confirmation of cancer presence [6]. A PSA serum level higher than 4 ng/mL,
currently adopted as marker, is not a sure sign of PCa, because it may reflect also inflammatory diseases
(e.g., prostatitis, irritations), non-cancer related benign prostatic hypertrophy (BPH) or diet alterations,
resulting in false positives [5]. Moreover, PSA test does not allow to differentiate aggressive PCa
from indolent diseases [7]. Therefore, a PBs is necessary for a final diagnosis [7]. However, PBs may
entails risks for patients (i.e., bleeding or subsequent infections) [8] and offers low levels of accuracy
(i.e., only 30% detection rate at first biopsy), especially when the tumour is small [9]. Therefore,
suspected patients should undergo repeated PBs in order to improve the detection rate. The inefficacy
of PCa screening programs result in patients’ overtreatment [6], and consequent increase of health
spending [10].
In order to improve the accuracy of the diagnosis, researchers are rising to the challenge of
developing innovative diagnostic tools able of identifying PCa during its early stage that is the most
curable [11]. Effective screening tests should be non-invasive, easily accessible, quickly quantifiable,
reliable, and reproducible [12,13]. They should have high sensitivity, specificity, low financial burden
on patients, and the lowest possible risk level [14]. An improvement of the design of screening
programs requires a better characterisation of the disease biology and the investigation of disease
dynamics and molecular diagnostics, which determines whether the cancer will be aggressive or
indolent, in order to avoid overtreatment [14].
Recent years have seen remarkable progresses in the characterisation and the quantification of
biological molecules and the explanation of their roles in cells, opening the possibility to identify
molecular changes and metabolic pathways specific for cancer [7].
Since metabolic alterations, typical of cell neoplastic transformation processes, lead to peroxidation
of membrane components and consequent release of volatile organic compounds (VOCs) [15],
the investigation of biological fluids can provide useful information about pathological conditions [7].
Therefore, the interest in their characterisation aimed at the identification of tumour-specific
compounds has increased significantly.
In the scientific literature, different approaches have been proposed. Many literary studies [16–24]
focused on the identification of a cancer-characteristic “odour fingerprint” emanated from biological
samples, instead of a detailed chemical mapping, through the application of sensorial or
senso-instrumental analyses. Other researchers [25–40] suggested a chemical characterisation of
biological fluids or of their gaseous headspace with the aim of identifying PCa-specific biomarkers.
Commonly, blood, urine, prostatic or seminal fluid, and prostate tissue, are analysed for
these purposes.
Blood is rich in human proteins, which are considered potential biomarkers for PCa detection
and prognosis. However, the masking effects of high-abundance compounds worsen the identification
of low-abundance proteins, because of the wide range of concentrations and the high amounts of
interfering compounds [41].
Prostate tissue is the best source of PCa specific biomarkers, but it is the most invasive, expensive,
and risky of sampling sites, entailing side effects such as bleeding or infections [6].
Semen provides information directly from the prostate, but it is characterised by high variability,
and it may be difficult to collect it in men with other diseases [7].
Urine has been investigated for centuries as source of useful information for the assessment of
diseases [42–45]. Because urine is the carrier of blood wastes, it may provide information not only
from kidney and urinary tracts, but also from distant organs via plasma obtained through glomerular
filtration [6]. Compared to other biological fluids, urine has the advantages of being inexpensive, rich in
metabolites, easy to handle, and available in large amounts, without requiring invasive treatments
for collection [46–49]. However, it is characterised by very low concentrations of possible biomarkers
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and high variability among patients depending on gender, age, hormonal status, diet, or physical
activity [50–53].
This paper focuses on the review of literary studies in the field of medical diagnostics about
innovative methods for early PCa detection based on the analysis of urine, considering a timeframe of
publication between 2008 and 2017. In particular, this review aims to provide an overview of innovative
methods for PCa diagnosis, thereby comparing them with the traditional diagnostic procedures.
The following sections provide a general overview of traditional diagnostic procedures (Section 2)
and of the state-of-the-art of alternatives proposed in recent years (Section 3). Innovative techniques
considered are grouped by type of study, according to the method adopted: sensorial methods
involving the use of high-trained dogs (Section 3.1.1), senso-instrumental methods based on the
adoption of electronic noses (Section 3.1.1), and analytical techniques based on the chemical
characterisation of urine (Section 3.2).
Given the huge number of possible techniques for the chemical characterisation of urine
samples [54], in this review, only approaches based on liquid or gas chromatography and mass
spectrometry were considered. These analytic techniques are the most consolidated and allow detecting
metabolites at very low concentrations with high sensitivity [54], although recent studies based
on magnetic resonance seem to be very promising, especially for the analysis of prostatic fluid or
tissue [55–57].
2. Overview of Traditional Diagnostic Methods
This section aims to give a general overview of the traditional diagnostic procedure for PCa
detection. The detailed description of the current diagnostic methods falls out of the scope of this
paper, besides, it is already object of other exhaustive reviews, papers, and books [58–62]; for this
reason, this section is limited to highlight the main issues of current diagnostics for further comparison
with the investigated innovative techniques.
Current screening for PCa is based on the measurement of prostate specific antigen (PSA) serum
level. The PSA is a 33 kDa serine protease responsible for the controlled release of sperm, which is
secreted into the fluid of the glandular ducts [3,63]. In a normal prostate, only small amounts (i.e.,
<4 ng/mL) of PSA reach the circulation system by leaking backwards into extracellular fluid and
diffusing into circulation [3]. Conversely, in case of PCa, PSA serum level is higher, because of the
derangement of epithelial cells architecture and polarisation, which causes the loss of normal secretory
pathways into the prostatic ducts [3].
Literature studies about PCa development [64,65] demonstrated that the concentration of serum
PSA and its doubling time or PSA velocity reflect the grow rate of PCa. However, PSA test is
characterised by low diagnostic accuracy (i.e., specificity around 33% and sensitivity around 86%) [9].
Indeed, higher PSA serum levels may be associated with other non-cancer related diseases, such as
prostatitis, irritations, benign prostatic hypertrophy (BHP), or also diet alterations [5]. Moreover,
PSA falsely diagnoses indolent PCa, which tends to grow and spread slowly. Thus, the lack of
diagnostic accuracy associated with this method often results in patients’ overtreatment, and increase
of health spending [66,67]. Approximately 10% of men over 50 years old have a PSA serum levels over
4 ng/mL, but among them, only 30% have a PCa confirmed by further investigations [3]. Wilt et al. [68]
proved that, after positive PSA test, patients who underwent radical prostatectomy did not have a
significant reduction in mortality with respect to those who opted for active surveillance over a 12 year
follow up.
Since PSA occurs in serum in various molecular forms (i.e., free PSA or complexes with inhibitors),
many efforts have been made to increase the diagnostic accuracy of PSA test through the quantification
of these different forms [69–71]. Although the consideration of different PSA molecular forms (ratio free
to total PSA, isoforms p2PSA) increases cancer detection rates [72,73], they are not useful for the
diagnosis of prostate cancer by itself [74].
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Therefore, in case of high PSA serum level, the patient usually undergoes digital rectal examination
(DRE). As most cancers are located in the peripheral posteriori area, DRE may detect bumps, soft or
hard spots, or abnormal masses [75]. However, DRE is not capable of detecting early PCa, because
a minimum tumour volume of 0.2 mL is needed for a possible diagnosis: DRE will detect a cancer
only in the 0.1–4% of asymptomatic men considered [75]. Patients having a normal DRE outcome,
though PSA serum level is markedly altered, will watchfully wait, repeat PSA and DRE periodically,
and undergo further invasive tests (i.e., the biopsy).
Transrectal ultrasound-guided prostate biopsies (PBs) provide the confirmation of PCa presence.
This exam is invasive, expensive, and risky. It may cause subsequent infections, erectile dysfunction,
and urinary incontinence [76]. Many studies have demonstrated that there is a significant increase of the
hospitalisation rate due to infections following biopsy [8,77]. Moreover, the overall cancer detection rate
is 30% at first biopsy [19,78,79]. Therefore, in general, repeated biopsies are performed to improve cancer
detection rate. Although the use of MRI has led to the implementation of new diagnostic strategies,
including the development of equipment that facilitates MRI/TRUS fusion-guided biopsies, and
consequently, the increase of the positive biopsy detection rate, there remains a need for standardisation,
technical improvements, and appropriate training of radiologists to guarantee sufficient quality and
reproducibility [80]. The current PCa diagnostic procedure is summarised in Figure 1.
Figure 1. Prostate cancer current diagnostic procedure. (DRE, digital rectal examination; PSA, prostate
specific antigen; PBs, transrectal ultrasound-guided prostate biopsy)
Considering the limits of the actual diagnostic procedure for PCa detection, the need of a more
accurate prognostic method able of reducing overtreatment of low risk patients, unnecessary biopsies
and radical prostatectomies is evident.
3. Innovative Techniques
Given the abovementioned issues related to the current diagnostic procedures for PCa, in recent
years, many researches [19,69,81] have focused on the development of more accurate diagnostic tests
compared to traditional ones. The main goal of this research field is the identification of cancer during
its early stage, in order to decrease mortality and treatment costs related to PCa. For this purpose,
new tests should be capable of providing accurate information about the prognosis and the most
adequate treatment plan to be adopted.
This review aims to provide an overview of the state-of-the-art of innovative diagnostic techniques
for early PCa detection based on urine analysis. The in-depth analysis of literature highlighted that
this research field is still in progress, and different approaches have been proposed as alternatives of
the current diagnostic procedure. Considering the differences between those approaches, for clarity
of exposure, we decided to group the considered literary works by the type of analysis proposed,
which are
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• sensorial analysis, which relies on the mammalian sense of smell;
• senso-instrumental analysis, which tries to gather information about the olfactory properties of
the analysed sample (urine) by means of specific instruments (i.e., electronic noses);
• chemical analysis, which relies on analytical techniques for the identification and quantification
of chemical compounds (e.g., GC-MS).
Sensorial and senso-instrumental analyses have, in common, the characterisation of the odour
emanated from biological samples aimed to the identification of a cancer-characteristic “odour
fingerprint”, thus considering the olfactory properties of urine as a whole [82–85]. As already
mentioned, sensorial methods are based on the direct characterisation of odours relying on the
general human or animal sense of smell. In the particular field of diagnostics, some researchers [15,86]
proved the capability of highly trained dogs to detect alterations of body odours associated with
specific illnesses.
Senso-instrumental methods are based on instruments that mimic the mammalian olfactory
system. Those instruments, commonly named electronic noses (EN), provide a global characterisation
of the odorous mixture. EN typically comprise an array of electronic chemical sensors with partial
specificity, and an appropriate pattern recognition system capable of recognising simple or complex
odours [87].
Conversely, chemical analyses are based on the chemical characterisation of liquid urine or its
headspace aiming to the detection of PCa biomarkers and the quantification of their amounts. They
provide a detailed chemical mapping of urine through the adoption of different analytic techniques,
such as gas or liquid chromatography coupled with mass spectrometry, solid phase microextraction or
ion exchange liquid chromatography [27,30,36].
3.1. Olfactory Fingerprint Investigation
It has long been known that VOCs emanating from biological fluids contain information about
the internal biochemistry of the human body. In ancient medicine, the diagnosis of different diseases
relied on the sensorial analysis of biological fluids. Hippocrates [88] attributed all diseases to disorders
of fluids, and proposed a diagnostic protocol that included observing skin and urine colour or
urine tasting.
In recent years, the diagnostic usefulness of biological fluid has been revaluated. Indeed, several
research studies [86,89,90] have been published regarding the investigation of biological fluid odours
with the aim of identifying the presence of VOCs that are specifically related to different diseases.
In the field of PCa diagnosis, some research groups proved the capability of highly trained dogs to
detect alterations of body odours associated with cancer, while others tried to develop instrumental
methods, proposing ENs as diagnostic tools.
3.1.1. Trained Dogs
Dogs are widely employed by police for detecting explosives and drugs and locating missing
persons [91,92]. Dogs’ olfactory system is capable of detecting odours as low as part per trillion [93],
thanks to characteristic anatomic factors, such as the increased dimension of their olfactory epithelium,
the huge number of olfactory receptors and the dense innervations of their olfactory mucosa [94].
The first trial investigating the feasibility of dogs’ adoption for early PCa detection through the
analysis of urine samples was published by Gordon et al. [16] in 2008. They trained four dogs of
different breeds to discriminate men affected by PCa from healthy volunteers by the clicker training
method. The training was performed by dogs’ owners, who followed the same general outline for
training protocol. During the training phase, cancerous urines were progressively presented to dogs
against empty test tubes, water, diluted control urines, and finally, full-strength control urines in order
to progressively complicate the system. In the latter training phase, dogs were presented with one
positive urine against six control samples. Then, dogs’ ability was tested in 33 blind runs. Each run
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contained six control samples and one cancerous urine placed in screw-top vial in randomised order.
Dogs’ performance in blind runs was worse than expected. Sensitivity achieved was around 20% for
all dogs involved, while specificity was higher than 60% only for two dogs. This outcome may be
explained, as suggested by the authors themselves, considering protocol deficiencies of training, i.e.,
absence of professional team of trainers, of a central training site and of a standardised procedure.
Cornu et al. [17] tested the ability of a Belgian Malinois shepherd to discriminate PCa and control
urines. The dog was trained by the clicker training method for 16 months. Then, it was involved in a
double-blind procedure that consisted of consecutive runs. For each run, the dog was presented five
controls and one cancer anonymised sample. For the analyses, urine samples, stored at−4 ◦C, were slowly
heated to 37 ◦C. The dog had to scent, successively, the six samples, and after a mean time of 30 s, it had
to sit in front of the cancer sample. In case of success, the sample was classified as true positive; otherwise,
it was considered as a false positive. Their study involved 59 men affected by PCa and 49 control subjects,
and no exclusion criteria regarding medical history, diet, drugs, or tobacco consumption was considered
in the selection of participants. All patients were classified as controls or PCa after undergoing PBs.
The descriptive analysis for dogs’ performance evaluation was performed with XLStat for Windows
(Addinsoft, Paris, France) and the sensitivity and specificity achieved were of 91%.
Elliker et al. [18] attempted to train ten dogs of seven different breeds for the PCa detection
adopting a two-stage training procedure. During the first stage of training, dogs learnt to find and
indicate PCa samples, while during the second phase, they became able to discriminate PCa samples
from controls. Urine samples were frozen at −20 ◦C within 10 min after collection, and defrosted in a
37 ◦C water bath before dogs’ examination. Following training, three double-blind tests were performed
for the two dogs that gave the best performances. During the blind test, the dogs were presented with
15 arrays, containing one PCa and three controls. The specificity achieved was 71% and 75% for the two
dogs, respectively, while the sensitivity was 13% and 25%. Those data were lower than expected by
chance. Probably the drop in sensitivity and specificity registered was due to the procedure adopted
for training and blind tests. In particular, during the training phase, samples from the same donors
were presented to dogs several times, and this may have led dogs to memorise sample-specific odour
fingerprint that they did not rediscover during the double-blind tests, since only samples from new
donors were considered. Indeed, comparison of the urine sample choices made by the dogs in different
tests suggested that each dog was using different odour signature for the sample selection.
This outcome emphasises the importance of using different urine samples for the training and the
double-blind tests. However, this outcome does not exclude the possibility that dogs could learn to
generalise based on a common PCa with an optimised training procedure.
In order to reach this goal, Taverna et al. [19] defined a rigorous procedure for dogs’ training aimed
at the identification of a pool of VOCs specific for PCa emanating from urine samples. Two German
Shepherd explosion detection dogs were trained using the clicker training. The dogs were taught
to sit in front of the cancerous sample after sniffing a set of six urine samples, including one PCa
sample and five controls. Urine samples were stored at −20 ◦C. For the analysis, 2 mL of each sample
were defrosted and housed in circular perforated metal containers. Metal containers were placed in
thermally sealed plastic packets to avoid any contamination.
Taverna’s research involved a huge and multifaceted population (i.e., 902 participants), including
also men and women suffering from different tumours. Diagnostic test performance was evaluated,
considering the whole population, after excluding females, and considering only control men older
than 45 years. In all cases, sensitivity was higher than 98% and specificity was over 96%.
In the attempt to resume and order the main information present in the scientific literature
regarding the use of trained dogs for PCa detection in a table, according to a common logic for the
readers’ use, the following categories were defined and used: involved population and trained dogs,
sample preparation, training methods, and diagnostic accuracy achieved in terms of sensitivity and
specificity [95–98] (Table 1).
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Table 1. Literary studies proposing trained dogs for urine analysis for early prostate cancer (PCa) detection.
Reference Authors Population Involved Controls/Sick Trained Dogs Samples Collection and Treatments Training Method Results
[16] Gordon et al.(2008) 186 57 PCa 4
Storage temperature: −20 ◦C;
Sample preparation: thawed, placed in a screw-top vial;
Sample somministration: screw-top vials were put into
mason jars
Training site: trainer’s home
Trainer: Owner
Duration: 12–14 months
Frequency: 2–7 d/w
Specificity:
1: 36%; 2: 36%;
3: 63%; 4: 81%
Sensitivity:
1: <10%; 2: <20%;
3: 20%; 4: 25%
[17] Cornu et al. (2010)
training phase: 16;
double blind
phase: 33
training phase: 26;
double blind
phase: 33
1
Storage temperature: −4 ◦C;
Sample preparation: slowly heating to 37 ◦C;
Sample somministration: samples placed in perforated
boxes
Trainer: Professional
Duration: 16 months
Frequency: 5 d/w
Specificity: 91%;
Sensitivity: 91%
[18] Elliker et al. (2014) 67 50 PCa 2
Storage temperature: −20 ◦C;
Sample preparation: defrosting in a 37 ◦C water bath;
Sample somministration: samples were put in open top
propylene test tubes
Stage 1: dogs had to find and
indicate PCa urine samples;
Stage 2: dogs had to
discriminate PCa samples from
controls; No information about
duration and frequency of
training
Specificity:
1: 71%; 2: 75%;
Sensitivity:
1: 13%; 2: 25%
[19] Taverna et al.(2015) 540 362 PCa 2
Storage temperature: −20 ◦C;
Sample preparation: defrosting to 37 ◦C;
Sample somministration: samples were put into
circular perforated metal containers placed in thermally
sealed plastic containers
Training Site: central
Trainer: professional No
information about duration and
frequency of training
Specificity:
1: 98.7%; 2: 97.6%;
Sensitivity:
1: 100%; 2: 98.6%
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3.1.2. Electronic Nose
Given the promising results reported in studies regarding the dogs’ capability of detecting PCa
by sniffing urine samples, some research groups [20–24] started investigating the possibility to transfer
those results to an instrumental method based on the analysis of urine samples through electronic
noses (EN).
Electronic noses are already adopted in the food and pharmaceutical industries [87,99,100],
in the environmental field [101] and for indoor air quality monitoring [102]. Their application to
diagnostics has been studied with promising results for discrimination of bacteria cultures [103,104],
or the detection of urinary tract infections [105–107], diabetes [108], kidney diseases [109,110], bowel
diseases [111,112] by means of urine analysis, and lung and colon cancers by means of exhaled breath
analysis [113].
In the field of PCa diagnosis, Bernabei et al. [20] investigated the ability of an EN based on 8 quartz
crystal microbalances coated with different metalloporphyrins, i.e., the ENQBE, to characterise urine
headspaces for the detection of PCa and bladder cancers (BC). The research involved 113 patients,
including other urological diseases in the control group and PCa post-surgical patients. For the creation
of urine headspace, the sample was kept at 25 ◦C for the time necessary to obtain a steady gaseous
mixture. Then, 10 mL of the enriched headspace were extracted and injected in a 2 L bag pre-filled
with N2.
Data were processed by means of principal component analysis (PCA) and discriminant analysis
solved by partial least squares (PLS-DA). The leave one out cross validation (LOOCV) was adopted to
evaluate the classification performance. The PCA score plot shows a good discrimination between PCa,
BC samples and controls. A very interesting result was the migration of post-surgical patients from
the PCa cluster to the healthy cluster, suggesting the ability of the EN not only to detect urological
diseases, but also to monitor the response to treatments.
D’Amico et al. [21] conducted a pilot study for PCa diagnosis using an EN equipped with
8 non-selective gas sensors, coated with metalloporphyrins. Urine samples were provided before
prostate biopsy by 21 volunteers, including men suffering from PCa and healthy subjects. Each control
participant provided two urine samples, thus executing two different trials. For the EN analysis,
urine was put in a sterile urine box with a dedicated top to extract the headspace to be analysed.
Data were processed by PLS-DA, and only a qualitative plot is reported for evaluating the
discrimination achieved. This study needs to be enlarged in terms of population involved. In particular,
the number of sick participants should be increased in order to create two olfactory classes,
approximately including the same number of subjects, otherwise, the classification may be biased
towards the class with most representatives. Moreover, the experimental procedure should be
standardised in order to confirm results.
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Asimakopoulos et al. [22] evaluated the efficacy of PCa detection by an EN equipped with
8 non-selective quartz crystal microbalance gas sensors coated with different metalloporphyrins,
based on the analysis of urine samples collected before prostate biopsy. Each participant was
asked to collect the initial part of the urination and the midstream in two different sterile vials.
The measurements were performed without knowing biopsy outcomes. A first aspect to be highlighted
is the different EN outcome related to the analyses of different parts of the urination. In particular,
the analysis of midstream urine did not provide useful information for PCa detection. Conversely,
the analysis of the first part of urine correlated with prostate biopsy outcomes. The author attributed
this result to an increased content of elements of prostatic secretions in the first part of the urines.
In this study, the EN performance achieved a sensitivity of 71.4% (CI 42–92%) and a specificity of 92.6%
(CI 76–99%).
Santonico et al. [23] resumed the study of D’Amico et al. [21] and analysed urine headspaces
of men suffering from PCa searching for specific odour fingerprints with the EN developed at the
University of Rome “Tor Vergata”. Measurements were performed at room temperature and data
were elaborated by means of PLS-DA using LOOCV. The test achieved a specificity of 93%. However,
the PLS-DA score plot showed only a partial discrimination of positive samples from controls.
Roine et al. [24] evaluated the EN ability of discriminating PCa from BPH by means of the
analysis of urine headspaces. They involved 50 patients with confirmed PCa, and 24 control subjects
suffering from BPH, among them, 15 patients provided urine preoperatively and 9 patients 3 months
postoperatively. Urines were collected in the morning, and samples were stored at −70 ◦C.
The EN used was a commercial model (i.e., ChemProR 100, Environics Inc., Mikkeli, Finland),
equipped with ion mobility cell consisting of 8 electrode strips and a metal oxide-based semiconductor
cell. For the analysis, urine was defrosted and pipetted to a polystyrene culture plate, which was
heated and maintained at 37 ◦C. Each measure lasted 25 min: 15 min for urine analysis and 10 min for
recovery. Sensitivity and specificity were, respectively, 78% and 67%, when using LOOCV, and 82%
and 88% when using LDA. Urine samples were collected only from men who required surgical
operation. The authors in the conclusions suggested extending the study, considering patients with
mild symptoms and the effects of other factors responsible for urine odour alterations, such as diet,
medications, or hydration.
Also for this technology, we tried to resume and schematise the main information gathered
from the scientific literature in a table. The logic adopted in this case involved the definition of
the following categories—besides authors and year of publication—population involved, sample
preparation methods, statistical methods adopted, and results achieved in terms of classification
performance (Table 2).
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Table 2. Literary studies proposing electronic nose (EN) adoption for PCa diagnosis through urine analysis.
Reference Authors Participants Controls/Sick Samples Collection and Treatments Instrument (SensorType)
Statistical
Methods Results
[20] Bernabei et al.(2007)
29 BPH; 33 other
urological
pathologies;
18 controls
25 BC
12 PCa
Urine collection: in the morning before any food intake;
Storage temperature: no info;
Headspace creation: urine was put at 25 ◦C for the
necessary time to obtain a steady headspace, then
10 mL of headspace were injected into a 2 L sterile bag
pre-filled with N2;
EN analysis: no info
ENQBE (Conducting
polymers)
PLS-DA; PCA;
LOOCV
qualitative plot;
discrimination between
PCa and BC samples and
controls 100%;
differentiation between
different classes, not
complete discrimination
[21] D’Amico et al.(2012) 15 6 PCa
Urine collection: before PBs;
Storage temperature: no info;
Headspace creation: a dynamic headspace was
obtained putting urine in sterile urine boxes with a
dedicated top;
EN analysis: no info
EN: University of
Rome “Tor Vergata”
(Conducting polymers)
PLS-DA qualitative plot
[22] Asimakopouloset al. (2014) 27 14 PCa
Urine collection: before PBs; Storage temperature: no
info;
Headspace creation: a dynamic headspace was
obtained putting urine in sterile urine boxes with a
dedicated top;
EN analysis: no info
EN: University of
Rome “Tor Vergata”
(Conducting polymers)
PLS-DA; LOOCV Sensitivity: 71.4%,specificity: 92.6%
[23] Santonico et al.(2014) 27 14 PCa
Urine collection: before PBs; Storage temperature: no
info;
Headspace creation: a dynamic headspace was
obtained putting urine in sterile urine boxes with a
dedicated top;
EN analysis: 200 s for the measurement phase, 600 s for
the cleaning phase
EN: University of
Rome “Tor Vergata”
(Conducting polymers)
PLS-DA; LOOCV qualitative plot
[24] Roine et al. (2014)
24 (15 BPH and
9 post radical
prostatectomy)
50 PCa
Urine collection: in the morning;
Storage temperature: −70 ◦C;
Headspace creation: urine was defrosted and pipetted
to a plate heated and maintained at 37 ◦C;
EN analysis: 15 min for the measurement phase, 10 min
for recovery
EN: ChemPRO
100-eNose (Electrode
strips and MOS
sensors)
LOOCV; LDA
LOOCV: sensitivity 78%,
specificity 67%, accuracy
77%
LDA: sensitivity 82%,
specificity 88%
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3.2. Chemical Analysis
Recent years have seen remarkable progresses in the characterisation and the quantification of
biological molecules and the explanation of their roles in cells, providing new pathways for diagnostic
purposes [114]. Metabolic alterations may be indicative of disease incidence, and may allow for
identification of cancer biomarkers [7], defined by National Cancer Institute as biological molecules
found in body fluids or tissues that are signs of normal or abnormal biological process or of a condition
or disease [115].
The discovery of new and more efficacious PCa biomarkers may improve current diagnostic
procedure, allowing determination of which patients will develop an aggressive tumour, prediction of
recurrence, and monitoring of response to treatments.
In this section, we tried to provide a general overview of literature works focused on the chemical
characterisation of liquid or gaseous urine aimed at early PCa detection.
Sreekumar et al. [25] proposed sarcosine, uracil, kynurenine, glycerol-3-phosphate, leucine,
and proline as PCa biomarkers. They reported that sarcosine was significantly higher in urine
sediments (accuracy AUC 71%) and supernatants (AUC 67%) of PCa patients, while uracil, kynurenine,
glycerol-3-phosphate, leucine, and proline were elevated upon disease progression.
Jentzmik et al. [26] involved 45 healthy subjects and 107 PCa patients. They determined sarcosine
levels in urine by GC-MS, using a commercial amino acid assay, and discovered that the median
sarcosine/creatinine was 13% lower in PCa patients than in controls. However, ROC analyses proved
the inefficacy of sarcosine as PCa biomarker in comparison with total PSA, since the discrimination
between PCa patients and controls was significantly worse. Authors recognised a limit of their study
in the higher proportion of PCa patients than healthy subjects.
Jiang et al. [27] developed a novel method for the quantification of six urinary metabolites suitable
as PCa biomarkers, i.e., sarcosine, proline, kynurenine, uracil, glycerol-3-phosphate, and creatinine,
and reported that their average concentrations were higher in PCa urine than controls.
Wu et al. [28] adopted microwave-assisted derivatisation (MAD) combined with GC-MS to
analyse urine samples from 20 PCa patients, 8 patients with BHP, and 20 healthy men, and compared
metabolic information. PCa patients’ average sarcosine levels were 13% higher than healthy controls
and 19% higher than BPH samples. Propenoic acid, dihyroxybutanoic acid, creatinine, xylonic acid,
and dihyroxybutanoic acid were proposed as PCa biomarkers, since their concentrations were higher
in PCa patients with respect to controls.
Stabler et al. [29] compared markers in serum and urine of patients with rapidly recurrent prostate
cancer to recurrence-free patients after radical prostatectomy. They tested methionine metabolites
in urine and serum as pre-surgical markers for aggressive disease. They reported that urinary
dimethylglycine and homocysteine of the groups did not differ significantly, while urinary sarcosine
and cysteine were significantly higher in recurrent patients.
Bianchi et al. [30] developed and validated a SPME-GC/MS method for the analysis of urine
and urinary sediments. Their results showed that sarcosine could be adopted as PCa biomarker.
Correspondence of a cut-off of 179 µgsarcosine/gcreatinine sensitivity of 79% and specificity of 87% were
achieved. Shamsipur et al. [31] combined dispersive derivatisation liquid–liquid microextraction
(DDLLME) with GC-MS and LC-MS to define a method for the determination of PCa metabolite
biomarkers, including sarcosine, alanine, leucine, and proline. They proved that sarcosine mean
concentration was higher in PCa patients, while leucine mean concentration was lower.
Struck-Lewicka et al. [32] reported that metabolites significantly changed in PCa patients
were mainly involved in amino acid, organic acid, sphingolipid, fatty acid, and carbohydrate
metabolic pathways. Glycine, serine, threonine, alanine, indole, hippurate, hydroxyhippurate,
tryptophan, kynurenate, tyrosine, indole acetate, indolelectate, quinate, phenylacetamide, glutamine,
isocitrate, aconitate, succinate, sucrose, sorbose, arabinose, arabitol, inositol, galactaric acid,
acetic, propanoic, propenoic, butanoic acid, dimethylheptanoyl, carnitine, propanoylcarnitine,
butyrylcarnitine, octanoylcarnitine, hydroxysphinganine, and C16 sphingosine were proposed
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as indicators of metabolic alterations due to PCa. All these metabolites were present at lower
concentrations in PCa samples with respect to controls.
Heger et al. [33] monitored the level of potential non-invasive PCa biomarkers responsible
for the genesis and the progression of the tumour. PSA and free PSA were determined by
immunoenzymometric assay too. They detected statistically significant differences in concentrations of
amino acids (i.e., aspartic acid, threonine, methionine, isoleucine, leucine, tyrosine, arginine, sarcosine,
proline) and biochemical parameters (i.e., concentrations of K+, uric acid, urea, and creatinine).
In particular, amino acids, urea, and creatinine were more abundant in PCa patients, while K+ and
uric acid concentrations were higher in controls.
Khalid et al. [34] investigated the VOCs emanating from urine samples. They proposed
2,6-dimethyl-7-octen-2-ol, pentanal, 3-octanone, 2-octanone as suitable biomarkers for PCa detection.
Except for pentanal, all of these compounds were downregulated and/or less frequently present in
the urine samples from PCa patients compared to healthy subjects. The accuracy of the model based
on four biomarkers discovered was 63–65%, while it was 74% (RF) and 65% (LDA), if combined with
PSA level.
Tsoi et al. [35] evaluated the potential role of urinary polyamines, i.e., putrescine (Put), spermidine
(Spd), and spermine (Spm), in PCa development. Their levels were determined by UPLC-MS/MS.
Spm demonstrated a good discrimination performance between PCa patients and BPH patients:
normalised Spm showed a significant decrease in PCa patients compared to non-cancerous cases,
including BPH patients. Correlations between urinary Spm had also been performed with patients’
pathologic characteristics, like age, serum PSA, creatinine content and prostate volume. However,
all of them showed weak correlation with correlation coefficients <0.1.
Sroka et al. [36] proposed the LC-ESI-QqQ-MS for the quantification of amino acids and amine
concentrations in urine samples from PCa patients and men with diagnosed BPH. They aimed to
determine whether amino acids and amine could be used to discriminate between PCa and BPH.
Arginine, homoserine, and proline were more abundant in samples from PCa patients compared
to patients with benign growth. Their study underlined also that patients classified with Gleason
score (GS) 7 had significantly higher concentrations of proline, homoserine, and tyramine compared
with those classified as GS 6 or GS 5. They also showed the inefficacy of sarcosine as PCa indicator,
by determining its levels before and after the prostate massage.
Fernandez-Peralbo et al. [37] identified 28 significant metabolites for PCa detection.
Dimethyllysine, 5-acetamidovalerate, acetyllysine, trimethyllysine, imidazole lactate, histidine,
methylhistidine, acetylhistidine, urea, acetylarginine, acetylcitrulline, acetylputrescine,
dimethylarginine, citrulline, tyrosine, 8-methoxykynurenate, kynurenic acid, xanthurenic acid,
sulfoacetate, isethionate, acetyltaurine, acetylaspartate, acetylaspartylglutamic acid, 2-oxoglutaramate,
2-pyrrolidone-5-carboxylate, 5-methyldeoxycytidine-5-phoshate, 7-methylguanosine were present
at lower concentrations in PCa urine samples than controls, while 7-methylguanine reported
higher concentrations in PCa patients. Those metabolites were used to develop a PLS-DA model,
which achieved 88.4% and 92.9% of sensitivity and specificity, respectively.
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Gkotsos et al. [38] measured sarcosine, uracil, and kynurenic acid concentrations by UPLC-MS/MS
and LC-ESI-MS/MS in urine from PCa patients, men with elevated PSA serum levels, and healthy
subjects. Decreased median sarcosine and kynurenic acid and increased uracil concentrations were
observed in PCa samples compared to controls. The ROC curve analysis showed that sarcosine and
uracil did not correlate with the clinical status of subjects considered. Contrarily, kynurenic acid
seemed a suitable PCa biomarker, especially in cases where the urine was collected after prostatic
massage. However, this metabolite cis not useful in order to monitor disease progression.
Derezinski et al. [39] presented a comprehensive analysis of amino acids in urine. Their study
provided strong evidence those branched-chain amino acids metabolic pathways can be a valuable
source of markers for prostate cancer. The univariate statistical analyses performed showed that,
in PCa samples, taurine was present at significant higher level, while γ-amino-n-butyric acid,
phosphoethanolamine, ethanolamine, homocitrulline, arginine, δ-hydroxylysine, and asparagine
occurred at significantly lower levels with respect to healthy samples. Moreover, γ-amino-n-butyric
acid, phosphoethanolamine, ethanolamine, homocitrulline, arginine, δ-hydroxylysine, asparagine,
cystathionine, and methionine had AUC higher than 75%. The PLS-DA model built on urine amino
acid levels achieved sensitivity and specificity of 89.47% and 73.33%, respectively, whereas the total
accuracy of classification was 82.35%.
In 2015, Aggio et al. [40] came up with a particular approach based on a “hybrid” system.
In particular, they proposed a GC-MOS system, comprising a GC oven fitted with a commercial
capillary column interfaced with a MOS sensor working at 450 ◦C, for classifying urine samples from
patients with urological symptoms. Their study included 58 men with PCa, 24 with BC, and 73 with
haematuria and/or poor stream, without cancer. The headspace was injected into the inlet of the
GC-sensor system, and the gas sensor signals were processed by PCA to visualise the discrimination
achieved. LDA and support vector machine (SVM) were used as statistical models to diagnose
unknown samples. The performance of the classifiers was validated by LOOCV, repeated 10FoldCV,
repeated DoubleCV, and Monte Carlo permutations. The first two principal components of the PCA
performed on dataset relevant to PCa and control samples show a good discrimination between the
two classes. In particular, the sensitivity reached was higher than 93%, while the specificity was
above 95%.
The same work of schematisation of the significant data and information contained in the—in this
case quite rich numbers of—scientific literature, was done for the papers regarding the application
of chemical analyses for PCa detection. Table 3, besides authors and years, reports the population
involved, the sample preparation methods, the analytical methods, the statistical methods, and the
biomarkers proposed.
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Table 3. Literary studies proposing different analytical techniques for PCa biomarker identification.
Reference Authors PopulationControls/Sick Sample Preparation Method Analytical Method Statistical Methods Biomarkers Results
[25] Sreekumaret al. (2009) 51/59
Urine collection: After DRE for PCa
patients;
Storage and pre-treatments: Samples were
stored at −80 ◦C until analysis;
Sample preparation: Samples underwent
organic and aqueous extractions. The
extracted was equally divided into LC and
GC fractions, which were dried on a
TurboVapR. Prior to injection, all samples
were resuspended in identical volume and
injection standards were added.
LC-MS: The vacuum dried sample was re-solubilised in
100 µL of injection solvent. The system was operated
using a gradient of acetonitrile. The columns were
maintained in temperature-controlled chambers during
use and were exchanged and washed after every
50 injections.
GC-MS: The column used was 5% phenyl-methyl
polysiloxane, the temperature from 40 ◦C to 300 ◦C in
16 min.
ID GC-MS: For analysing sarcosine and alanine,
residual water was removed by forming an azeotrope
with 100 uL of DMF and drying the suspension under
vacuum. An Agilent 6890N GC equipped with a 15 m
DB-5capillary column interfaced with an Agilent 5975
MSD mass detector.
Wilcoxon rank-sum test;
t-test; Kruskal–Wallis
test; Pearson’s
correlation;
NOVA; Z-score plot;
heat maps
Sarcosine; Uracil;
Kynurenine;
Glycerol-3-phosphate;
Leucine; Proline
Sarcosine was significantly
higher in urine sediments
(AUC 71%) and supernatants
(AUC 67%) of PCa patients;
Uracil, Kynurenine,
Glycerol-3-phosphate,
Leucine, Proline were
elevated upon disease
progression.
[26] Jentzmiket al. (2010) 45/107
Urine collection: after DRE for PCa
patients; Second morning void urine for
healthy participants;
Storage and pre-treatments: Samples were
centrifuged (1500× g, 10 min, 4 ◦C) and
stored at −80 ◦C;
Sample preparation: no info
Ez:fast amino acid analysis: SPME followed on a L-LE
with the subsequent GC-MS on a 5973 MS and 6890 GC
system. Recovery was checked with samples spiked
with known amounts of sarcosine.
Mann–Whitney U test;
Wilcoxon matched-pairs
test; Spearman rank
correlation; Fischer’s
exact test; ROC analysis
Sarcosine
Median Sarcosine/creatinine
was 13% lower in PCa
patients than in controls
[27] Jiang et al.(2010) 5/5
Urine collection: no info;
Storage and pre-treatments: Samples were
frozen at −80 ◦C;
Sample preparation: Samples were thawed
at room T and diluted 3 times using water;
10 µL of diluted urine were mixed with 10
µL of the internal standard solution and
1480 µL of 0.1% formic acid in water; those
samples were diluted 450 times and
injected for HPLC/MS/MS analysis
HPLC: An LC system working at 25 ◦C under a flow
rate of 250 µL/min using a gradient system with the
mobile phase consisting of (A) 0.1% formic acid in
water and (B) 0.1% formic acid in acetonitrile (100%)
was used for metabolite separation. The gradient
program was initial 98% A and 2% B, linear gradient to
60% A and 40% B in 5 min, and return to initial
conditions in 0.1 min at a flow rate of 250 µL/min,
followed by equilibration for 10 min.
MS/MS: An API 4000Q trap MS/MS system operated
in multiple-reaction monitoring mode with ESI-positive
ionisation was used. Turbo Spray was used as the ion
source. The capillary voltage was set at 5.5 kV. Nitrogen
gas was used as the curtain gas and cone gas. The cone
gas flow was 50 L/h, and the desolvaation gas flow was
800 L/h. Optimal detection conditions were determined
by direct infusion of each standard solution (20 ppb) in
solvent A using a syringe pump. Parent-ion and
daughter-ion scans were performed using nitrogen as
the collision gas at a pressure of 3.8 × 103 millibar and a
flow of 0.2 mL/min.
Multivariate statistics
Sarcosine; Proline;
Kynurenine; Uracil;
Glycerol-3-phosphate;
Creatinine
nMmetabolites/µMcreatinine:
PCa patients: Sarcosine 120;
Proline 40; Kynurenine 15;
Uracil 10;
Glycerol-3-phosphate 85;
Controls: Sarcosine 30;
Proline 5; Kynurenine 8;
Uracil 5;
Glycerol-3-phosphate 30
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Reference Authors PopulationControls/Sick Sample Preparation Method Analytical Method Statistical Methods Biomarkers Results
[28] Wu et al.(2010)
8 BHP; 20 healthy
male/20
Urine collection: first morning urine;
Storage and pre-treatments: Samples were
centrifuged within 1 h at 3000 rpm for
10 min at 25 ◦C; aliquoted in 1 mL and
stored at −80 ◦C;
Sample preparation: Samples were
thawed by incubation at 37 ◦C for 3 min
and vortex-mixed for 15 s. 800 µL
methanol, 100 µL ribitol and 100 µ were
added into each sample and vortex-mixed
for 5 min and ultrasonicated at room T for
5 min. pH was adjusted to 9–10 with
NaOH and solution was filtered by
0.45 µm membrane. 100 µL of filtrate were
transferred to a screw vial and evaporated
under N2
ID GC-MS: 1 µL of derivatised sample was injected
splittless into an Agilent 6980 GC equipped with a 30 m
× 0.25 nm i.d. fused-silica capillary column with
0.25 µm HP-5MS stationary phase. Injector T was set at
250 ◦C, column T was initially kept at 80 ◦C for 3 min
and increased to 280 ◦C at 10 ◦C/min, where it was
held for 2 min. Column effluent was introduced into
Agilent 5973 mass selective detector: quadrupole T
150 ◦C, ion source T 230 ◦C, solvent delay 180 s.
Two-sample t test; PCA;
ROC analysis
Sarcosine; Propenoic acid;
Pyrimidine;
Dihyroxybutanoic acid;
Creatinine; Purine;
Glucopyranoside;
Ribofuranoside; Xylonic
acid; Xylopyranose
PCa patients average
sarcosine value were 13%
higher than healthy controls
and 19% higher than BPH
controls. Also propenoic acid,
dihyroxybutanoic acid,
creatinine, and xylonic acid,
dihyroxybutanoic acid and
xylonic acid, concentrations
were higher in PCa patients.
[29] Stabler et al.(2011)
29 recurrent free;
25 PCa recurrence
Urine collection: before prostatectomy;
Storage and pre-treatments: Samples were
stored at −80 ◦C;
Sample preparation: no info
GC-MS: A Durabond DB.1 fused silica capillary column
(30 m × 0.25 mm) from J&W Scientific, Inc. and a
Hewlett-Packard Co. 5992B gas chromatograph-mass
spectrometer equipped with a falling needle injector
were used.
Wilcoxon rank sum test;
Fisher exact test;
Spearman’s rank
correlation
Cysteine; Homocysteine;
Dimethylglycine; Sarcosine
Higher serum homocysteine,
cystathionine, and cysteine
levels independently
predicted risk of early
biochemical recurrence and
PCa aggressiveness. The
methionine further
supplemented known clinical
variables to increase
sensitivity and specificity.
[30] Bianchi et al.(2011) 13 healthy; 10 BHP/33
Urine collection: after DRE;
Storage and pre-treatments: no info;
Sample preparation: no info
SPME: A Gerstel MultiPurpose Sampler DualRail
WorkStation MPS autosampler equipped with two
sample trays, two-heated incubator shakers, a 100 µL
syringe and a 3-position trays MFX was used. Hexyl
chloroformate (10 µL), 10 µL of pyridine and 10 µL of
hexanol were added, under continuous agitation at 500
rpm, in 0.9 mL clear crimp vials with sleeve for 10 × 32
vial containing 400 µL of urine. Norvaline was used as
internal standard. After 5 min, 20 µL were diluted in 0.9
mL clear crimp vials previously filled with 800 µL of
water. Simultaneously, the SPME fibres were
transported between the 3-position tray and the vial.
Urine sediments were washed with water under
sonication and filtered. The filter was then broken up
adding 500 µL of HCl and 1 mL of acetone into a 10 mL
vial placed in an ultrasound bath for 10 min. Extraction
was performed using PDMS/DBV fibre that was
immersed in vial for 15 min at 35 ◦C. A constant
magnetic stirring was applied. The desorption was
carried out at 260 ◦C for 1 min.
GC-MS: Oven setting was as follows: 80 ◦C for 0.3 min,
80 ◦C min−1 up to 200 ◦C, 200 ◦C for 0.3 min, 50 ◦C
min−1 up to 290 ◦C. Inlet pressure, column flow and
average linear velocity were 623.1 kPa, 0.97 mL min−1
and 51.3 cm s−1. The QP 2010 series MS detector
(Shimadzu) equipped with the acquisition system GC
Solution software was operated under the selected ion
monitoring mode by applying a delay time of 2.9 min
Mann–Whitney U;
Kruskal–Wallis tests;
ROC analysis
Sarcosine; N-ethylglycine
µgSarcosine/gCreatinine
discriminates between
healthy, BHP and PCa
patients
Cut-off 179 µg/g:
sensitivity 79%; specificity
87%
Cancers 2018, 10, 123 16 of 29
Table 3. Cont.
Reference Authors PopulationControls/Sick Sample Preparation Method Analytical Method Statistical Methods Biomarkers Results
[31] Shamsipuret al. (2012) 20/12
Urine collection: no info;
Storage and pre-treatments: sample were
frozen at −22 ◦C;
Sample preparation: urine was thawed at
room T and shaken vigorously for 1 min
DDLLME: 4 mL of water spiked with standard solution
were treated with 12 M NaOH to obtain the desired pH.
Standard amino acids were spiked into the solution at a
level of 200 µg/L for initial screening and 50 µg/L for
final optimisation. 150 µL acetonitrile, 200 µL pyridine
and 25 µL carbon tetrachloride were added and the
solution was mixed vigorously for 15 s. i-BuCF (250 µL)
were added and shaken for 30 s. The solution was left to
stand for 1 min and then centrifuged at 2260× g for
4 min for phase separation. 10 µL of the sediment phase
was injected into the GC-MS for analysis.
GC-MS: Processed samples were analysed using an
Agilent 6890 GC coupled to an Agilent 5973 inert EI/CI
mass selective detector. He was maintained at a
constant flow of 1.8 mL min−1. The injection port was
set to splitless and maintained at an optimised
temperature of 280 ◦C. The oven temperature program
was as follows: 80 ◦C (initial temperature), ramped to
155 ◦C at 10 ◦C min−1, holding at 155 ◦C for 5 min, then
ramped to 172 ◦C at 2 ◦C min−1 holding for 2 min,
finally ramped to 280 ◦C at 40 ◦C min−1 and holding
for 6 min. T settings for the transfer-line heater, ion
source, and quadrupole of the MS were 280, 150, and
150 ◦C, respectively. The dwell time for each scan was
150 ms ion−1, and the solvent delay was 7 min. The
electron impact ionisation energy was 70 eV.
Bland-Altman Sarcosine; Alanine; Proline;Leucine
Sarcosine mean
concentrations were higher in
PCa patients; Leucine mean
concentration was lower in
PCa patients
[32] Struck-Lewickaet al. (2014) 32/32
Urine collection: no info;
Storage and pre-treatments: Samples were
stored at −80 ◦C;
Sample preparation: no info
LC-TOF/MS: Urine samples after thawing at room
temperature were vortex-mixed for 1 min and
centrifuged at 4000× g for 10 min. Subsequently the
supernatant was diluted in deionised water and then
centrifuged at 4000× g for 15 min. After centrifugation,
the samples were filtered directly to HPLC vials using
0.2 µm nylon filters.
GC-MS: samples were thawed at room temperature for
1 h. The first step was addition of 50 µL of urease to
200 µL of urine. Next, the sample incubation in 37 ◦C
for 30 min was applied (to decompose and remove
excess amount of urea). Next, 800 µL of cold methanol
(kept for 30 min in −80 ◦C) and 10 µL of pentadecanoic
acid were added to urine samples. Then the samples
were vortex-mixed for 5 min and centrifuged at 4000 g
for 15 min. 200 µL of supernatants were transferred into
glass inserts in GC vials and evaporated to dryness in
30 ◦C for 1 h 30 min. Next, 30 µL of methoxyamine in
pyridine in concentration of 15 mg/mL was added to
urine samples. The next step was vortex-mixing of each
sample for 10 min and then incubation of all samples
for 16 h in room temperature in dark place. The
silylation process was performed with addition of 30 µL
of BSTFA with 1% TMCS, vortex-mixing of each sample
for 5 min and incubation for 1 h in 70 ◦C. Before GC-MS
analysis, addition of 70 µL of hexane and vortex-mixing
for 10 min were performed
MFE algorithm; PCA;
PLS-DA; 7-fold cross
validation
35 metabolites
LC-TOF/MS: Positive
ionisation mode R2 0.756, G2
0.579; Negative ionisation
mode R2 0.763, G2 0.508
GC-MS: R2 0.788, G2 0.711
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[33] Heger et al.(2014) 32/32
Urine collection: no info;
Storage and pre-treatments: 500 µL of
urine were mixed with 500 µL of 35% HCl
and mineralised using the microwave
equipment MW 3000. 100 µL of
mineralised sample were diluted with
900 µL of dilution buffer and centrifuged
using Centrifuge 5417R. 500 µL of the
sample were diluted in 500 µL of 0.6 M
NaOH;
Sample preparation: no info
IELC: A glass column with an inner diameter of 3.7 and
length of 350 mm was filled manually with strong
cation exchanger in sodium cycle with ~12 µm particles
and 8% porosity. The column was thermostated at
60 ◦C. Double channel VIS detector with an inner cell of
5 µL was set to two wavelengths: 440 and 570 nm.
Elution of amino acids was carried out by buffer
containing 10.0 g of citric acid, 5.6 g of sodium citrate,
and 8.36 g of natrium chloride per litre of solution
(pH 3.0). The flow rate was 0.25 mL·min−1. The reactor
temperature was set to 120 ◦C.
IEMA: The immunoenzymometric assay was used for
analysis of PSA and fPSA
Shapiro–Wilk test; t test;
hierarchical clustering
aspartic acid, threonine,
methionine, isoleucine,
leucine, tyrosine, arginine;
sarcosine; proline;
concentrations of K+, Na+,
Cl−, uric acid, urea, PSA,
glucose, total proteins,
fPSA, creatinine and pH
All amino acids were
increased in PCa patients,
except for phenylalanine
amounts. In controls, higher
levels of K+ and uric acid and
lower levels of urea and
creatine were detected. PSA
and free PSA were below the
detection limit in controls.
[34] Khalid et al.(2015) 43/59
Urine collection: no info;
Storage and pre-treatments: Samples were
stored at −20 ◦C;
Sample preparation: Each sample was
defrosted by immersing the vial in a water
bath at 60 ◦C for 30 s. One single aliquot of
urine sample per patient was used for
VOC analysis. Thereafter, each sample was
treated with an equal volume (0.75 mL) of
sodium hydroxide 1 M.
The mixture was equilibrated at 60 ◦C in a
water bath for 30 min prior to SPME.
SPME: The SPME fibre was 85 µm thick and consisted
of carboxen/polydimethylsiloxane. It was exposed to
the headspace above the urine mixture for 20 min.
GC-MS: VOCs were thermally desorbed from the fibre
at 220 ◦C in the injection port of the GC/MS for 5 min.
Injection was made in splitless mode and a split of
50 mL/min was turned on two minutes into the run. It
was used helium as carrier gas (99.996% purity).
Capillary column consisted of 94% dimethyl
polysiloxane and 6% cyanopropyl-phenyl. The GC/MS
T program of the run was as follows: initial oven T was
held at 40 ◦C for 2 min then T was ramped up at a rate
of 5 ◦C/min to 220 ◦C, with a 4 min hold at this T to
give a total run time of 42 min. The mass spectrometer
was run in electron impact (EI) ionisation mode,
scanning the mass ion range 10–300 at 0.05 scan/s.
A 4 min solvent delay was used at the start of the run.
Random Forest; LDA;
10-fold cross validation;
double cross validation
2,6-dimethyl-7-octen-2-ol;
Pentanal;
3-octanone;
2-octanone
Except for pentanal, all of
these compounds were
down-regulated and/or less
frequently present in the
urine samples from PCa
patients. Model AUC based
on 4 biomarkers discovered
was 63–65%, while it was 74%
(RF) and 65% (LDA) if
combined with PSA level.
[35] Tsoi et al.(2016) 88 BHP; 11 healthy/66
Urine collection: after lunch prior PBs;
Storage and pre-treatments: −20 ◦C;
Sample preparation: Firstly, urine samples
were thawed and centrifuged for 5 min at
13,000 rpm at room T. Urine sample
supernatant (120 µL) and 60 µL of internal
standard working solution were mixed
with 420 µL of water. Of this well-mixed
solution, 550 µL was passed through SPE,
which had been conditioned and
equilibrated with 1 mL of methanol and
water respectively. Water (450 µL) was
passed through the cartridge afterwards to
elute out all polyamines. Of these
SPE-treated samples, 400 µL were then
mixed with 100 µL of 10% HFBA, and the
final mixture was ready for instrumental
analysis
UPLC-MS/MS: The column used was an Agilent
EclipsePlus C18 RRHD (2.1 × 50 mm, 1.8 µm) protected
with an Agilent SB-C18 guard column (2.1 × 5 mm,
1.8 µm). The LC elution profiles were optimised as
follows: Eluent A was water with 0.1% HFBA while
eluent B was acetonitrile with 0.1% HFBA. Eluent A
was decreased from 95% to 60% in 10 min, and from
60% to 10% in 1 min. Afterwards the gradient was held
constant for 5 min. The gradient was then increased
from 10% to 95% in 1 min, and held constant for 8
additional minutes. The autosampler and column
temperatures were set at 4 and 35 ◦C respectively.
Injection was achieved by 5-s needle wash in Flush Port
mode for 3 times with eluent B. Ten microlitres was
injected each time. For the source parameter, drying gas
(N2) temperature was set as 300 ◦C with 5 L/min flow
rate. Nebuliser pressure was 45 psi. Sheath gas
temperature was set as 250 ◦C with 11 L/min flow rate.
Capillary voltage was set as 3500 V.
Student’s t-test; ROC
analysis
putrescine (Put),
spermidine (Spd) and
spermine (Spm)
Normalised Spd was
significantly lower in PCa
than in BHP patients and
controls
The AUC for normalised Put,
Spd and Spm were found to
be 0.63 ± 0.05, 0.65 ± 0.05
and 0.83 ± 0.03 respectively
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[36] Sroka et al.(2016) 25 BHP/25
Urine collection: prior and after prostate
massage;
Storage and pre-treatments: Sodium azide
solution was added. Samples were stored
at −80 ◦C;
Sample preparation: 10 µL aliquot of each
urine sample or standard solution was
added to 70 µL of 200 mM borate buffer
containing 25 µM 2-Aminobutyric acid,
1 mM ascorbic acid and 10 mM TCEP. The
solution was vortexed, centrifuged. 20 µL
of 10 mM Aqc reagent dissolved in
100%ACN was added. The solution was
vortexed, centrifuged, heated with shaking
at 55 ◦C for 10 min.
LC-ESI-QqQ-MS: Mobile phase consisted of (A) 0.1%
formic acid in water (v/v) and (B) 0.1% formic acid in
ACN (v/v). Flow rate was set to 300 µL min−1.
Separation was performed at 30 ◦C with monitored
pressure below 400 bar. Analysis time was 19 min. The
gradient was run from 0–2 min using 1% solvent B, then
linearly raised over 7 min from 1% to 15% solvent B.
then raised to 30% solvent B over 5 min and dropped to
1% for re-equilibration which lasted 5 min.
Concentrations were quantified using Agilent 1200
LC-system coupled to an Agilent 6410 ESI-QqQ-MS.
Injection volumes of 2 µL of samples or standards were
used. Ions were monitored in the positive ion mode.
Source conditions were set to sheath gas temperature
315 ◦C. Gas flow 10 L min−1. nebuliser pressure 45 psi
and capillary voltage 3800 V.
t-test; U Mann-Whitney
analysis; ROC curves
Arginine; Homoserine;
Proline; Tyramine
In PCa samples, higher
concentrations of arginine
both before (p = 0.018) and
after (p = 0.009) prostate
massage and higher levels of
proline only after prostate
massage (p = 0.032) were
detected. Higher levels of
proline and homoserine and
tyramine correlate with GS7
with respect to GS 6 and GS 5.
[37] Fernandez-Peralboet al. (2016) 42/62
Urine collection: prior PBs
Storage and pre-treatments: Samples were
stored at −80 ◦C
Sample preparation: After thawing at
room T, urine samples were vortex-mixed
for 1 min and centrifuged at 21,000× g for
5 min. Then, 50 µL of the supernatant were
1:2 (v/v) diluted with 5 mM ammonium
formate in water (pH 5.5–7.5)
LC-QTOF: A Mediterranea Sea C18 analytical column
thermostated at 25 ◦C was used. The initial mobile
phase was a mixture of 98% phase A (0.1% formic acid
in water) and 2% phase B (0.1% formic acid in ACN).
After injection, the initial mobile phase was kept under
isocratic conditions for 1 min; then, a linear gradient of
phase B from 2% to 100% was applied within 16 min.
The flow rate was 0.6 mL/min. The total analysis time
was 17 min, and 5 min were required to re-establish the
initial conditions. The injected volume was 5 µL. The
autosampler was kept at 4 ◦C to increase sample
stability.
unpaired t-test (p-value
< 0.05);
PLS-DA
28 metabolites
Almost all metabolites were
present at lower
concentrations in PCa
patients than in controls,
Training: Specificity 92.9%;
Sensibility 88.4%
Validation: Specificity 78.6%;
Sensibility 63.2%
[38] Gkotsos et al.(2017) 49/52
Urine collection: second morning void
midstream;
Storage and pre-treatments: −80 ◦C after
post-centrifugation (each sample
centrifuged at 1500× g, for 10 min, at 4 ◦C);
Sample preparation: 100 µL of sample was
diluted with 100 µL of MeOH. The
samples were vortex-mixed (1 min) and
centrifuged for 10 min (7000 g) to remove
particulate matter and macromolecules.
50 µL of supernatant was diluted with
100 µL of MeCN and transferred to LC/MS
vial, which was maintained at 10 ◦C.
UPLC-MS/MS: Separation was performed on a
ACQUITY UPLC™ BEH AMIDE column 1.7 µm,
2.1 mm × 150 mm suitable for polar metabolites.
Sarcosine, uracil, and kynurenic acid were detected
using Multiple Reaction Monitoring (MRM) mode in a
single injection of 15.5 min. The MRM transitions for
the three metabolites were set as follows: sarcosine m/z
90–44, CV = 20 V, CE = 8 V; uracil m/z 113–70, CV = 40 V,
CE = 15 V; and kynurenic acid m/z 190–172, CV = 32 V,
CE = 12 V. For chromatographic separation the mobile
phase was a mixture of (A) ACN/H2O, 95:5 v/v and (B)
H2O/ACN, 70:30 v/v both with final ammonium
formate buffer concentration of 10 Mm and elution was
performed with a gradient program started with 100%
A, then rising to 15% B linearly over the next 2 min,
finally reaching 40% B over 2 min and returning to
initial conditions over 5 min. The column was
equilibrated for 6 min in the initial conditions. Flow
rate was 0.5 mL/min
Kruskal–Wallis test;
ROC analysis; Pearson
correlation;
Orthogonal Projections
to Latent Structures
Discriminant Analysis
(OPLS-DA)
Sarcosine; Uracil; Kynurenic
acid
Decreased median sarcosine
and kynurenic acid and
increased uracil
concentrations were observed
for patients with prostate
cancer compared to
participants without
malignancy.
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Table 3. Cont.
Reference Authors PopulationControls/Sick Sample Preparation Method Analytical Method Statistical Methods Biomarkers Results
[39] Derezinski etal. (2017) 40/49
Urine collection: second morning void
midstream;
Storage and pre-treatments: −80 ◦C after
post-centrifugation (each sample
centrifuged at 1500× g, for 10 min, at 4 ◦C);
Sample preparation: 100 µL of sample was
diluted with 100 µL of MeOH. The
samples were vortex-mixed (1 min) and
centrifuged for 10 min (7000 g) to remove
particulate matter and macromolecules.
50 µL of supernatant was diluted with
100 µL of MeCN and transferred to LC/MS
vial, which was maintained at 10 ◦C.
LC-ESI-MS/MS combined with aTRAQ: HPLC
instrument 1260 Infinity combined with a 4000 QTRAP
mass spectrometer with an EI source. The column was
maintained at 50 ◦C with a flow rate of 800 µL/min. A
mobile phase gradient of eluent A (0.1% formic acid
and 0.01% heptafluorobutyric acid in water) and eluent
B (0.1% formic acid and 0.01% heptafluorobutyric acid
in methanol) was applied. The gradient profile was the
following: from 2% to 40% of B from 0 till 6 min,
maintained at 40% of B for 4 min, then increased to 90%
of B till 11 min and held at 90% of B for 1 min. After
12 min the gradient decreased to 2% of B. From 13 to
18 min the mobile phase composition was unaltered.
The injection volume was set at 2 µL. The mass
spectrometer operated in positive ionisation mode with
the following parameters: entrance potential, 10 V;
declustering potential, 30 V and collision cell exit
potential, 5 V. Collision energy of 30 eV was applied
with the exception of cystathionine, cysteine,
homocysteine, argininosuccinic acid, hydroxylysine,
lysine, and ornithine (50 V). Scheduled multiple
reaction monitoring mode was used with nitrogen as a
collision gas. Data acquisition and processing were
performed using the Analyst 1.5 software.
Mann-Whitney U test,
Student’s t-test, Welch’s
F test, ROC curve
analysis, PLS-DA,
Shapiro-Wilk test
1-methylhistidine,
3-methylhistidine, Alanine,
arginine, argininosuccinic
acid, asparagine, aspartic
acid, citrulline, carnosine,
39 metabolites
In PCa samples, taurine was
present at significant higher
level, while γ-amino-
The PLS-DA model built on
selected metabolites achieved
sensitivity and specificity of
89.47% and 73.33%,
respectively, whereas the total
group membership
classification value was
82.35%.
[40] Aggio et al.(2015)
73 with haematuria
and poor stream
without cancer/58
PCa; 24 BC
Urine collection: before PBs
Storage temperature: −20 ◦C
Headspace creation: samples were
defrosted in water bath at 60 ◦C for 30 s,
mixed with 0.75 mL of 1 M sodium
hydroxide, reimmersed in water bath at
60 ◦C for 50 min
EN analysis: 2 cm3 of headspace were
extracted and analysed
Hybrid GC-MOS sensor system: It is composed of a
gas chromatography (GC) oven fitted with a
commercially available capillary column interfaced to a
heated (450 ◦C) metal oxide sensor (MOS chemresistor
composite of tin oxide and zinc oxide 50:50 by wt). The
injection port of the GC was fitted with a 1 mm quartz
linear and heated to 150 ◦C. Cylinder air at 35 psi was
used as carrier gas. The temperature program was:
30 ◦C held for 6 min, up to 100 ◦C at 5 ◦C/min, hold
100 ◦C for 22 min. Volatile organic compounds (VOCs)
exiting the GC column reach the MOS sensor, which
resistance was recorded.
LOOCV;
DoubleCV;
SVM-P;
Monte Carlo
permutation
none
LOOCV: sensitivity 95%,
specificity 96%;
DoubleCV: sensitivity 87%,
specificity 99%;
SVM-P: sensitivity with
respect to BC 78%;
Monte Carlo permutation:
chance-like accuracy 50%
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4. Discussion and Conclusions
In the previous paragraphs, we tried to give an overview of the innovative techniques that are
being studied in the field of PCa diagnosis. This section has the aim of critically discussing the different
methods proposed, and to compare them in terms of advantages, drawbacks, and future perspectives.
In general, innovative tools proposed in recent years can be grouped into two macro-categories,
according to the method adopted. Many authors explored the possibility of analysing urine odour
fingerprint, while others preferred the chemical characterisation of liquid urine or of its gaseous
headspace, trying to identify potential PCa biomarkers. All approaches propose the comparative
analysis of urine samples from healthy men and PCa patients with the aim of discriminating the
two classes.
Studies reporting the adoption of trained dogs for PCa detection proved its feasibility and
the diagnostic accuracy achieved in terms of sensibility and specificity was promising. However,
they boosted further investigation, since some critical issues about the definition of the experimental
protocol emerged. In particular, the type of training and blind test, the training site, the team of trainers
involved, the frequency and duration of training, the method adopted for the sample somministration
and the number of blind-test runs influence dogs’ discriminative ability. In addition, it is worth
considering the high costs related to dogs’ training and the effect of the training procedure on the
classification performance.
Considering the limits related to the adoption of trained dogs for the development of
a large-scale diagnostic tool, researchers started investigating the possibility to transfer those
experimental observations to an instrumental method based on the analysis of urine samples through
electronic noses.
All literary works, summarised in Table 2, reporting the adoption of the EN for PCa diagnosis,
focused on the characterisation of urine headspace. In general, published results confirm the capability
of the EN to distinguish between urine samples collected from men suffering from PCa and healthy
subjects, with very promising diagnostic accuracy in terms of specificity and sensitivity, although there
is no uniformity concerning sample preparation, analysis, and data processing techniques among the
different studies proposed.
It is worth considering that none of the abovementioned studies address the problem of
sensor response drift over time, and repeatability among different instruments. Sensor drift (i.e.,
non-deterministic temporal variations of the sensor response when exposed to the same analytes
under identical conditions) is recognised as one of the main problems associated with gas sensor [116].
This aspect limits the EN ability to operate over long time periods in all fields of application of ENs,
thus, it is one of the key criticalities to be solved for the development and spread of an innovative PCa
diagnostic tool based on EN analysis.
Recent advances in the understanding of cancer genesis and progression and in the
characterisation and the quantification of biological molecules boosted the research in the field of urine
chemical characterisation for PCa diagnostic purposes. Indeed, many research groups started working
on the identification of novel biomarkers able to improve the diagnostic and prognostic accuracy of
the traditional tests.
Most of investigated literary works, summarised in Table 3, proposed the comparative analysis of
samples from PCa patients and controls, since authors agreed that PCa development caused alterations
of different metabolic pathways, such as amino acid, fatty acid, and carbohydrate metabolism.
They developed diverse methods, combining different analytical techniques, for the detection and
quantification of changes in metabolites levels in PCa samples compared to healthy ones. Sometimes,
different stages of the tumour were considered to evaluate also the efficacy of staging of proposed
PCa biomarkers.
Nevertheless, the in-depth analysis of these literary works highlighted that no exhaustive results
have been published until now, since many different metabolites were proposed as suitable PCa
biomarkers, and divergent opinions upon the same metabolites emerged in different studies.
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Many literary works considered proposed a quantitative characterisation of urine samples. Table 4
reports concentrations trends of proposed biomarkers in cancerous samples compared to controls,
as reported in literature.
Table 4. Concentrations of proposed biomarkers in PCa samples with respect to controls.
Biomarkers Proposed
Concentrations in PCa Samples with Respect Controls
Increasing Trend Decreasing Trend
Sarcosine [25,28–31] [36,38]
Isoleucine [33] [32,39]
Threonine [33] [32,39]
Proline [31,33,36–38] -
Citrulline [31,33,36–38] -
Homocitrulline [31,33,36–38] -
Histidine - [37,39]
Methylhistidine - [37,39]
Serine - [32,39]
Methionine [33] [39]
Tyrosine [33] [32,37,39]
Arginine [36] [39]
kynurenic acid [27] [38]
Uracil [27,38] -
Glutamine - [32,39]
Among the proposed biomarkers, the most debated is sarcosine. Indeed, many authors [25,28–31]
reported that its level in urine from PCa patients is higher than in control samples, and that its
classification performance is good, whereas other researchers [36,38] showed that changes in its
concentrations between PCa and healthy men were not statistically significant.
Isoleucine, threonine, methionine, tyrosine, arginine, and kynurenic acid trends in PCa and
control groups were debated too. In fact, Struck-Lewicka et al. [32], Fernandez-Peralbo et al. [37], and
Derezinski et al. [39] reported lower levels in PCa samples compared to controls, while Heger et al. [33],
Jiang et al. [27], and Sroka et al. [36] reported opposite trends.
Proline, citrulline, and homocitrulline seemed to be the most suitable biomarkers for PCa detection,
since many authors [27,31,33,36–38] agreed that their levels were higher in PCa samples compared to
control ones, and classification performance of models built on these metabolites was encouraging.
Future works should focus on those disparities among different studies, in order to adopt chemical
analyses with the objective of improving traditional diagnostic procedures.
The key aspects of different approaches discussed in this section were schematically compared in
terms of pros and cons as reported in Table 5.
Table 5. Advantages and disadvantages of different approaches reviewed.
Approaches Considered Pros Cons
Trained dogs Highest diagnostic accuracyachieved
Influence of the discriminative ability on
experimental protocol adopted; expensive and
time-intensive dog training
Electronic noses Rapid and relative inexpensiveanalysis
No uniformity concerning sample preparation,
analysis and data processing techniques
Chemical analysis Identification and quantification ofpossible PCa biomarker
Divergent opinions upon the concentrations of
same metabolites in PCa samples with respect
to controls; time-intensive analysis
Considering the specific and different difficulties associated with each of the discussed innovative
diagnostic approaches, possibly the evolution towards “hybrid” systems combining two or more
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different approaches, as proposed by Aggio et al. [40], might represent an answer to those contradictory
outcomes in the next future.
It is realistic to think of a possible future development of a “hybrid” system based on the
combination of the odour analysis performed by the EN with the chemical characterisation of urine
samples, which should differ from previous studies in this field by focusing on odour analysis, and take
unique advantage of the olfactory differences highlighted by EN analysis. This might possibly focus
on the identification of those compounds responsible for the alteration of urine odour, thus simplifying
the task of the chemical characterisation of urine and provide an innovative pathway for the discovery
of new and more efficient biomarkers specific for the PCa.
In general, one aspect that is common to all innovative diagnostic methods is the importance of
the size of the population involved. In particular, the classes considered (i.e., PCa patients and healthy
subjects) should include approximately the same number of samples, otherwise, the output of the
innovative tests tend to be biased towards the class with most representatives [117]. Almost all literary
works here presented involved small populations and, in many cases, the control and the PCa groups
were not numerically comparable.
Another very important critical point is that the majority of studies do not discuss the specificity
of the method towards PCa with respect to other pathologies. Indeed, it would be very interesting to
investigate the specificity to other types of tumours, and especially, tumours associated with the urinary
tract (i.e., bladder and kidney cancers). This aspect is particularly important for the development of a
specific diagnostic tool whose answer should be ideally positive only in cases of PCa, and negative for
any other disease, as obtained by Taverna et al. [19] in his experience with trained dogs.
Only Bernabei et al. [20] and Aggio et al. [40] tested the their methods towards another urological
tumour, i.e., the bladder cancer. Bernabei et al. [20] reported a PLS-DA score plot that showed the
complete discrimination between healthy and sick subjects and a PCA score plot, where the gradual
discrimination between different cancers is visible. On the contrary, Aggio et al. [40] reported only the
performance of the EN in distinguishing between controls and BC or PCa separately.
Roine et al. [24], Wu et al. [28], Bianchi et al. [30], Tsoi et al. [35] and Sroka et al. [36] included in
their chemical comparative studies men suffering from BPH, which typically causes a high number of
false positives in traditional procedures. However, their results should be confirmed by considering
larger populations.
One aspect common to the different methods proposed, which is worth highlighting here as part of
the critical discussion, is the importance of the training phase, which should be intended as the effective
training of dogs for developing the discriminative ability between different urine samples, and for
the development of a suitable model for data processing and classification for senso-instrumental and
chemical approaches.
According to the scientific literature here examined, it is not possible to identify a data processing
or classification algorithm whose classification performance clearly prevails compared to others.
Indeed, the proposed algorithms are sometimes very different from each other (e.g., PCA, PLS-DA,
ROC analysis, Mann–Whitney analysis, Pearson correlation) and this result in the variability of
classification performances reported. However, it is worth highlighting that mathematics, even when
involving extremely elaborate and complex algorithms, can never adjust bad data [118]. Therefore, it is
very important to optimise input data, especially when samples are characterised by high variability,
as with urine. This is a crucial aspect of this research field aimed at the development of a large-scale
PCa diagnostic tool.
Last but not least, a fundamental aspect for the development of a method that might become
of widespread use in clinical diagnosis is the switch from a complex laboratory apparatus to an
easy-to-use instrument. The training of dogs, the use of electronic noses or of chemical analysers,
require highly specialised personnel, whereas the field of clinical diagnosis is rapidly evolving towards
point-of-care tests, which ideally should be used by non-specific staff. This is a great challenge for
current research in the field of medical diagnostics.
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Despite the difficulties associated with the development of innovative and reliable diagnostic
techniques, a significant increase of the research in this field—and hopefully the successful introduction
of some of these techniques in clinical diagnosis—in the near future is to be expected, due to the
high social and economic impact that new technologies for early diagnosis of cancer might have in
today’s culture.
As a last consideration, it might be worth highlighting that, given the ambitious purpose, only a
multidisciplinary team, that includes clinicians, engineering, biologists, physicians, and biochemical
scientists, collaborate together to understand the complexity of human beings. This way of thinking
may further help to clarify concepts and indicate alternative experiments in order to develop
appropriate diagnostic methods [42].
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Abbreviations
10FoldCV repeated 10-fold cross validation
ACN acetonitrile
AUC accuracy
BC bladder cancer
BHP benign prostate hypertrophy
CI confidence interval
DDLLME dispersive derivatisation liquid–liquid microextraction
DMF dimethylformamide
DoubleCV double cross validation
DRE digital rectal examination
EN electronic nose
ESI electrospray ionisation
GC-MS gas chromatography-mass spectrometry
GS Gleason score
LC-MS liquid chromatography-mass spectrometry
LDA linear discriminant analysis
LOOCV leave one out cross validation
MAD microwave assisted derivatisation
MOS metal oxide semiconductors
PBs transrectal ultrasound-guided prostate biopsy
PCa prostate cancer
PCA principal component analysis
PLS-DA partial least squares discriminant analysis
PSA prostate specific antigen
Put putrescine
RF random forest
ROC receiver operating characteristics
Spd spermidine
Spm spermine
SPME solid phase microextraction
SVM support vector machine
SVM-P Support vector machine-polynomial
UPLC ultra-high performance liquid chromatography
VOCs volatile organic compounds
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